Autoimmune Diseases  >>  adomeglivant (LY2409021)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
adomeglivant (LY2409021) / Eli Lilly
NCT01640834: Study of LY2409021 in Participants With Type 1 Diabetes

Completed
1
20
Europe
LY2409021, Placebo, Glucagon
Eli Lilly and Company
Diabetes Mellitus, Type 1
09/12
09/12

Download Options